• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症抗血管生成治疗多学科转化试验的经验教训。

Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer.

作者信息

Jain Rakesh K

机构信息

Edwin L. Steele Laboratory for Tumour Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Cox-7, Boston, Massachusetts 02114, USA.

出版信息

Nat Rev Cancer. 2008 Apr;8(4):309-16. doi: 10.1038/nrc2346.

DOI:10.1038/nrc2346
PMID:18337733
Abstract

The importance of multidisciplinary translational clinical trials is obvious; however, making them work is complex and challenging. Here I present an argument for designing and implementing multidisciplinary mechanistic trials and present the lessons our team at the Massachusetts General Hospital Cancer Center has learned from two such trials in cancer patients with locally advanced rectal carcinomas and recurrent glioblastomas.

摘要

多学科转化性临床试验的重要性不言而喻;然而,要使其发挥作用却复杂且具有挑战性。在此,我提出设计和实施多学科机制性试验的理由,并介绍我们麻省总医院癌症中心团队从针对局部晚期直肠癌和复发性胶质母细胞瘤患者的两项此类试验中所学到的经验教训。

相似文献

1
Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer.癌症抗血管生成治疗多学科转化试验的经验教训。
Nat Rev Cancer. 2008 Apr;8(4):309-16. doi: 10.1038/nrc2346.
2
Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.当前癌症个体化抗血管生成治疗的关注点与挑战。
Expert Rev Anticancer Ther. 2009 Oct;9(10):1413-6. doi: 10.1586/era.09.116.
3
Promises and pitfalls of anti-angiogenic therapy in clinical trials.临床试验中抗血管生成疗法的前景与隐患
Trends Mol Med. 2003 Feb;9(2):53-8. doi: 10.1016/s1471-4914(03)00002-9.
4
The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials.对血管生成替代标志物的探索:肿瘤血管生成与抗血管生成试验中转化研究的范例。
Curr Mol Med. 2003 Dec;3(8):673-91. doi: 10.2174/1566524033479410.
5
Anti-angiogenic therapies for children with cancer.癌症患儿的抗血管生成疗法。
Curr Cancer Drug Targets. 2010 Dec;10(8):879-89. doi: 10.2174/156800910793357899.
6
Targeting small molecules in cancer.靶向癌症中的小分子。
Cancer Treat Res. 2007;135:239-55. doi: 10.1007/978-0-387-69219-7_18.
7
Antiangiogenic therapy at a crossroads: clinical trial results and future directions.抗血管生成疗法处于十字路口:临床试验结果与未来方向。
J Clin Oncol. 2003 Dec 1;21(23 Suppl):281s-283s. doi: 10.1200/JCO.2003.09.134.
8
Metabolic effects of anti-angiogenic therapy in tumors.肿瘤抗血管生成治疗的代谢效应。
Biochimie. 2012 Apr;94(4):925-31. doi: 10.1016/j.biochi.2012.01.001. Epub 2012 Jan 11.
9
Antiangiogenic strategies and agents in clinical trials.临床试验中的抗血管生成策略与药物
Oncologist. 2000;5 Suppl 1:20-7. doi: 10.1634/theoncologist.5-suppl_1-20.
10
Antivascular cancer treatments: imaging biomarkers in pharmaceutical drug development.抗血管生成癌症治疗:药物研发中的成像生物标志物
Br J Radiol. 2003;76 Spec No 1:S83-6. doi: 10.1259/bjr/15255885.

引用本文的文献

1
Synergistic mechanotherapy and sonopermeation guided by mathematical modeling for solid tumor treatment.基于数学建模指导的协同机械疗法和声透疗法用于实体瘤治疗
Front Drug Deliv. 2025 Jun 24;5:1549098. doi: 10.3389/fddev.2025.1549098. eCollection 2025.
2
Implementation of a clinical research "One Signature Initiative" at a large academic medical center.在一家大型学术医疗中心实施一项临床研究“一人签名倡议”。
J Clin Transl Sci. 2024 Nov 29;8(1):e221. doi: 10.1017/cts.2024.667. eCollection 2024.
3
Investigation of Gastrointestinal Toxicities Associated with Concurrent Abdominal Radiation Therapy and the Tyrosine Kinase Inhibitor Sunitinib in a Mouse Model.
在小鼠模型中研究与腹部放射治疗和酪氨酸激酶抑制剂舒尼替尼同时使用相关的胃肠道毒性。
Int J Mol Sci. 2024 Feb 2;25(3):1838. doi: 10.3390/ijms25031838.
4
The strange Microenvironment of Glioblastoma.脑胶质瘤的奇异微环境。
Rev Neurol (Paris). 2023 Jun;179(5):490-501. doi: 10.1016/j.neurol.2023.03.007. Epub 2023 Mar 22.
5
The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients.伊立替康-贝伐珠单抗作为低级别胶质瘤患儿的解救方案:72 例患儿的全国性回顾性研究。
J Neurooncol. 2022 Apr;157(2):355-364. doi: 10.1007/s11060-022-03970-4. Epub 2022 Mar 3.
6
Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer.血管正常化以改善 COVID-19 的治疗:从癌症治疗中得到的启示。
Clin Cancer Res. 2021 May 15;27(10):2706-2711. doi: 10.1158/1078-0432.CCR-20-4750. Epub 2021 Mar 1.
7
Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer.晚期上皮性卵巢癌系统治疗相关影像学表现概述。
Abdom Radiol (NY). 2020 Mar;45(3):828-841. doi: 10.1007/s00261-019-02175-0.
8
6-Gingerol stabilized the p-VEGFR2/VE-cadherin/β-catenin/actin complex promotes microvessel normalization and suppresses tumor progression.6-姜酚稳定 p-VEGFR2/VE-钙黏蛋白/β-连环蛋白/肌动蛋白复合物,促进微血管正常化并抑制肿瘤进展。
J Exp Clin Cancer Res. 2019 Jul 2;38(1):285. doi: 10.1186/s13046-019-1291-z.
9
Valproic Acid Induces Endothelial-to-Mesenchymal Transition-Like Phenotypic Switching.丙戊酸诱导内皮-间充质转化样表型转换。
Front Pharmacol. 2018 Jul 11;9:737. doi: 10.3389/fphar.2018.00737. eCollection 2018.
10
MP0250, a VEGF and HGF neutralizing DARPin molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models.MP0250是一种能中和血管内皮生长因子(VEGF)和肝细胞生长因子(HGF)的设计锚蛋白重复结构域蛋白(DARPin)分子,在小鼠异种移植瘤模型和患者来源的肿瘤模型中显示出高抗肿瘤疗效。
Oncotarget. 2017 Oct 11;8(58):98371-98383. doi: 10.18632/oncotarget.21738. eCollection 2017 Nov 17.